A COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF JEEVANIYA VATI (medicated tablet) AND GARBHA POSHANA VATI (medicated tablet)IN THE MANAGEMENT OF UPAVISTAKA W.S.R TO IUGR
Phase 2
- Conditions
- Health Condition 1: O365- Maternal care for known or suspected poor fetal growth
- Registration Number
- CTRI/2019/01/016892
- Lead Sponsor
- DR CHAITRA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
PREGNANT WOMEN AGED BETWEEN 18-35 YEARS
BOTH PRIMI AND MULTIGRAVIDA
PREGNANT WOMEN DIAGNOSED WITH UPAVISTAKA IN 28TH TO 32ND WEEKS OF GESTATIONAL AGE
PREGNANT WOMEN DIAGNOSED WITH ASYMMETRIC IUGR
Exclusion Criteria
PATIENTS HAVING HISTORY OF ANY OTHER SYSTEMIC ILLNESS THAT MAY INTERFERE WITH THE COURSE OF TREATMENT
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EFFICACY OF INTERVENTION OVER FETAL WEIGHT GAINTimepoint: From 7 month to date of delivery for 3 months
- Secondary Outcome Measures
Name Time Method ILTimepoint: NI
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Jeevaninya Vati and Garbha Poshana Vati efficacy in IUGR management?
How do Ayurvedic formulations Jeevaninya Vati and Garbha Poshana Vati compare to standard-of-care for IUGR fetal growth outcomes?
Which biomarkers correlate with improved maternal-fetal outcomes in CTRI/2019/01/016892 IUGR trial?
What adverse events are associated with Jeevaninya Vati and Garbha Poshana Vati in maternal care for IUGR?
Are there combination therapies involving Jeevaninya Vati and Garbha Poshana Vati for IUGR management in maternal care studies?